Foresee Pharmaceuticals (6576) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 逸達

Foresee Pharmaceuticals (6576) reported revenue of NT$125.1 million for Oct 2026, +397.5% year on year and +1,895.4% from the previous month. Revenue for Jan–Oct 2026 was NT$450.4 million (+11.4% year on year).

In Oct 2026, it ranked No. 64 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$115.8 million24/10Nov 2024 NT$9.6 millionDec 2024 NT$15.1 millionJan 2025 NT$11.1 millionFeb 2025 NT$70.9 million25/02Mar 2025 NT$28.4 millionApr 2025 NT$58.8 millionMay 2025 NT$13.9 millionJun 2025 NT$38.9 million25/06Jul 2025 NT$8.9 millionAug 2025 NT$141.8 millionSep 2025 NT$6.3 millionOct 2025 NT$25.2 million25/10Nov 2025 NT$13 millionDec 2025 NT$14.1 millionJan 2026 NT$12.8 millionFeb 2026 NT$27.1 million26/02Mar 2026 NT$40.4 millionApr 2026 NT$52.2 millionMay 2026 NT$118.5 millionJun 2026 NT$10.9 million26/06Jul 2026 NT$30.3 millionAug 2026 NT$26.7 millionSep 2026 NT$6.3 millionOct 2026 NT$125.1 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$125.1 million+397.5%+1,895.4%
Sep 2026NT$6.3 million-1.1%-76.5%
Aug 2026NT$26.7 million-81.1%-11.7%
Jul 2026NT$30.3 million+242.1%+176.7%
Jun 2026NT$10.9 million-71.8%-90.8%
May 2026NT$118.5 million+749.6%+126.9%
Apr 2026NT$52.2 million-11.2%+29.1%
Mar 2026NT$40.4 million+42.5%+49.3%
Feb 2026NT$27.1 million-61.8%+111.7%
Jan 2026NT$12.8 million+14.8%-9.3%
Dec 2025NT$14.1 million-6.5%+8.9%
Nov 2025NT$13 million+34.3%-48.5%
Oct 2025NT$25.2 million-78.3%+296.7%
Sep 2025NT$6.3 million-74.9%-95.5%
Aug 2025NT$141.8 million+640.8%+1,501.6%
Jul 2025NT$8.9 million-75.2%-77.2%
Jun 2025NT$38.9 million+22.4%+178.7%
May 2025NT$13.9 million+10.9%-76.3%
Apr 2025NT$58.8 million+18.0%+107.3%
Mar 2025NT$28.4 million-33.2%-60.0%
Feb 2025NT$70.9 million+148.3%+536.9%
Jan 2025NT$11.1 million-66.0%-26.2%
Dec 2024NT$15.1 million-47.5%+56.5%
Nov 2024NT$9.6 million-64.2%-91.7%
Oct 2024NT$115.8 million+810.2%+358.4%

Jan–Oct 2026 cumulative: NT$450.4 million (+11.4% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Foresee Pharmaceuticals vs PEC / Foresee Pharmaceuticals vs Lotus Pharm / Foresee Pharmaceuticals vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

本月營收較去年同期增加,係因本期認列新劑型新藥Camcevi授權開發里程金收入,去年同期並無所致。

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16